Vor Bio

Vor Bio is a clinical-stage biotechnology company focused on developing novel cell and genome engineering therapies for the treatment of acute myeloid leukemia (AML) and other blood cancers. Their unique approach aims to "shield" healthy cells by genetically modifying hematopoietic stem cells (HSCs) from a healthy donor. This modification, known as "trem-cel," removes specific cell surface targets that are shared between healthy blood cells and cancer cells, enabling the safe administration of targeted therapies like antibody drug conjugates (ADCs) and chimeric antigen receptor T (CAR-T) cells post-transplant.

Vor Bio is currently conducting two clinical trials for AML and MDS. Their VBP101 trial is evaluating the safety and efficacy of trem-cel in combination with Mylotarg™, a CD33-directed targeted therapy. Their VBP301 trial is investigating VCAR33ALLO, a donor-derived CD33-directed CAR-T cell therapy, in patients who have relapsed following allogeneic stem cell transplant. By advancing these innovative therapies, Vor Bio aims to transform the treatment landscape for patients with blood cancers, offering them a potentially curative option.

Vor Bio values its employees and offers a flexible work environment. While specific details about remote work options or schedules are not explicitly stated on the provided pages, the company emphasizes its commitment to fostering a culture of collaboration and mentorship, suggesting a willingness to accommodate individual needs and preferences within the team.

Vor Bio offers competitive and comprehensive employee benefits that exceed the needs of their employees and their families. The company provides a range of benefits including health insurance, dental insurance, vision insurance, life insurance, short-term and long-term disability insurance, paid time off, paid holidays, parental leave, a 401(k) plan with a company match, and other perks.

Vor Bio is a clinical-stage cell and genome engineering company focused on developing a novel treatment approach for blood cancers, particularly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). Their mission is to change the standard of care for these patients by engineering shielded transplants, a process that modifies hematopoietic stem cells to enable targeted therapies post-transplant, potentially leading to longer-term remissions and cures.

Vor Bio fosters a collaborative and innovative culture, valuing diversity and individual contributions. They encourage open communication, mentorship, and a relentless pursuit of progress, while also prioritizing a fun and supportive work environment. The company celebrates successes and encourages learning from failures, creating a dynamic and engaging atmosphere where everyone feels valued and empowered to make a difference in the fight against cancer.

Vor Bio is committed to fostering a culture of Diversity, Equity, Inclusion and Belonging (DEIB) where everyone feels valued and respected. They believe diversity in backgrounds, expertise, and perspectives is a strength that sets them apart as individuals and as a company. They strive to create an inclusive environment where everyone can contribute their unique talents and feel a sense of belonging. Vor Bio is proud to be an equal opportunity employer.